丙泊酚抗肿瘤作用及分子机制在肺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2021.05.018

Abstract

Abstract: Lung cancer is the most common malignant tumor.Surgical resection is the main method for the treatment of lung cancer.However,postoperative tumor recurrence and metastasis may still occur after surgery.Propofol is the most commonly used intravenous general anesthetic.In recent years,more and more documents have shown that propofol can prolong the survival period of patients with lung cancer.In this paper,by searching relevant literature,it is concluded that propofol regulates a variety of signal pathways to play a direct anti-cancer effect by regulating microRNA(miRNA)and circular RNA(circRNA).Propofol promotes T cell differentiation,improves immunity,reduces inflammatory mediators and indirectly inhibits the activity of cancer cells.Propofol can also increase the sensitivity of tumor cells to chemotherapy drugs and exert indirect anti-tumor effects.In addition,clinical trials have also confirmed that propofol may be closely related to the survival of cancer patients due to its anti-tumor properties.Therefore,the use of propofol intravenous general anesthesia in lung cancer surgery may be more suitable,but it still needs to be confirmed by large-scale prospective clinical trials.

Key words: Propofol, Lung cancer, MicroRNA, Circular RNA, Immunity

CLC Number:

R730.56

WU Changshuai, ZHANG Baohui, GAO Zhenglian, ZHANG Xiaowang, WANG Kun. Research progress in anti-tumor effect of propofol and its molecular mechanism in lung cancer[J]. Journal of Practical Oncology, 2021, 35(5): 480-484.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.05.018

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I5/480

References

1 Siegel RL,Miller KD,Jemal A.Cancer statistics[J].CA Cancer J Clin,2020,70(1):7-30.
2 Longhini F,Bruni A,Garofalo E,et al.Anesthetic strategies in oncological surgery:not only a simple sleep,but also impact on immunosuppression and cancer recurrence[J].Cancer Manag Res,2020,12:931-940.
3 Sahinovic MM,Struys MMRF,Absalom AR.Clinical pharmacokinetics and pharmacodynamics of propofol[J].Clin Pharmacokinet,2018,57(12):1539-1558.
4 Liu Z,Zhang J,Hong G,et al.Propofol inhibits growth and invasion of pancreatic cancer cells through regulation of the miR-21/Slug signaling pathway[J].Am J Transl Res,2016,8(10):4120-4133.
5 Zhang J,Zhang D,Wu GQ,et al.Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microR-NA-199a and downregulating MMP-9 expression[J].Hepatobiliary Pancreat Dis Int,2013,12(3):305-309.
6 Zhang F,Wang C,Cui Y,et al.Effects of propofol on several membrane characteristics of cervical cancer cell lines[J].Cell Physiol Biochem,2016,40(1-2):172-182.
7 Zhang L,Wang N,Zhou S,et al.Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2[J].J Exp Clin Cancer Res,2012,31:66.
8 Meng C,Song L,Wang J,et al.Propofol induces proliferation partially via downregulation of p53 protein and promotes migration via activation of the Nrf2 pathway in human breast cancer cell line MDA-MB231[J].Oncol Rep,2017,37(2):841-848.
9 Farazi TA,Spitzer JI,Morozov P,et al.miRNAs in human cancer[J].J Pathol,2011,223(2):102-115.
10 Wojczakowski W,Kobylarek D,Lindner J,et al.MicroRNAs-novel biomarkers for malignant pleural effusions[J].Contemp Oncol(Pozn),2019,23(3):133-140.
11 Wang Q,Liu S,Zhao X,et al.MiR-372-3p promotes cell growth and metastasis by targeting FGF9 in lung squamous cell carcinoma[J].Cancer Med,2017,6(6):1323-1330.
12 Sun H,Gao D.Propofol suppresses growth,migration and invasion of A549 cells by down-regulation of miR-372[J].BMC Cancer,2018,18(1):1252.
13 Zheng X,Dong L,Zhao S,et al.Propofol affects Non-Small-Cell lung cancer cell biology by regulating the miR-21/PTEN/AKT pathway in vitro and In vivo[J].Anesth Analg,2020,131(4):1270-1280.
14 Han M,Liu M,Wang Y,et al.Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN[J].PLoS One,2012,7(6):e39520.
15 Wu X,Li X,Xu G.Propofol suppresses the progression of non small cell lung cancer via downregulation of the miR 21 5p/MAPK10 axis[J].Oncol Rep,2020,44(2):487-498.
16 Yang DD,Kuan CY,Whitmarsh AJ,et al.Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene[J].Nature,1997,389(6653):865-870.
17 Liu WZ,Liu N.Propofol inhibits lung cancer A549 cell growth and Epithelial-Mesenchymal transition process by upregulation of MicroRNA-1284[J].Oncol Res,2018,27(1):1-8.
18 Yang N,Liang Y,Yang P,et al.Propofol inhibits lung cancer cell viability and induces cell apoptosis by upregulating microRNA-486 expression[J].Braz J Med Biol Res,2017,50(1):e5794.
19 Qu S,Yang X,Li X,et al.Circular RNA:a new star of noncoding RNAs[J].Cancer Lett,2015,365(2):141-148.
20 Zhang Z,Xie Q,He D,et al.Circular RNA:new star,new hope in cancer[J].BMC Cancer,2018,18(1):834.
21 Yu T,Wang Y,Fan Y,et al.CircRNAs in cancer metabolism:a review[J].J Hematol Oncol,2019,12(1):90.
22 Cui J,Li W,Liu G,et al.A novel circular RNA,hsa_circ_0043278,acts as a potential biomarker and promotes non-small cell lung cancer cell proliferation and migration by regulating miR-520f[J].Artif Cells Nanomed Biotechnol,2019,47(1):810-821.
23 Zhao H,Wei H,He J,et al.Propofol disrupts cell carcinogenesis and aerobic glycolysis by regulating circTADA2A/miR-455-3p/FOXM1 axis in lung cancer[J].Cell Cycle,2020,19(19):2538-2552.
24 Vaupel P,Mayer A.Hypoxia in cancer:significance and impact on clinical outcome[J].Cancer Metastasis Rev,2007,26(2):225-239.
25 Rankin EB,Giaccia AJ.Hypoxic control of metastasis[J].Science,2016,352(6282):175-180.
26 Yang N,Liang Y,Yang P,et al.Propofol suppresses LPS-induced nuclear accumulation of HIF-1α and tumor aggressiveness in non-small cell lung cancer[J].Oncol Rep,2017,37(5):2611-2619.
27 Javadian M,Gharibi T,Shekari N,et al.The role of microRNAs regulating the expression of matrix metalloproteinases(MMPs)in breast cancer development,progression,and metastasis[J].J Cell Physiol,2019,234(5):5399-5412.
28 Wu KC,Yang ST,Hsia TC,et al.Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells[J].Anticancer Res,2012,32(11):4833-4842.
29 Jett JR,Hatfield AK,Hillman S,et al.Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated,extensive-stage small cell lung carcinoma:a phase II trial of the North Central Cancer Treatment Group[J].Cancer,2003,97(10):2498-2503.
30 Huang Y,Lei L,Liu Y.Propofol improves sensitivity of lung cancer cells to cisplatin and its mechanism[J].Med Sci Monit,2020,26:e919786.
31 Cui WY,Liu Y,Zhu YQ,et al.Propofol induces endoplasmic reticulum(ER)stress and apoptosis in lung cancer cell H460[J].Tumour Biol,2014,35(6):5213-5217.
32 Ren XF,Li WZ,Meng FY,et al.Differential effects of propofol and isoflurane on the activation of T-helper cells in lung cancer patients[J].Anaesthesia,2010,65(5):478-482.
33 Tian HT,Duan XH,Yang YF,et al.Effects of propofol or sevoflurane anesthesia on the perioperative inflammatory response,pulmonary function and cognitive function in patients receiving lung cancer resection[J].Eur Rev Med Pharmacol Sci,2017,21(23):5515-5522.
34 Ke W,Zhang L,Dai Y.The role of IL-6 in immunotherapy of non-small cell lung cancer(NSCLC)with immune-related adverse events(irAEs)[J].Thorac Cancer,2020,11(4):835-839.
35 Sen Y,Hu XY,Yu H.Effect of thoracic paraspinal block-propofol intravenous general anesthesia on VEGF and TGF-β in patients receiving radical resection of lung cancer[J].Medicine(Baltimore),2019,98(47):e18088.
36 韩金玉,赵洪伟,宋振国.丙泊酚对肺癌患者围术期肿瘤微转移的影响[J].临床麻醉学杂志,2020,36(3):257-261.

[1]	WANG Ye, SHANG Naijian. Application progress of radiomics in the diagnosis and treatment of non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 485-488.
[2]	REN Siying, CHEN Yang, SHI Qingping, ZHU Yunfang, WEN Hongmei. Characteristics of lung cancer incidence and mortality from 2011 to 2016 in the cancer registration areas of Yunnan province and its time trend [J]. Journal of Practical Oncology, 2021, 35(4): 332-338.
[3]	WEI Donghua, MA Yanling, ZHANG Juan, YIN Huiping, ZHANG Xiaopeng, ZHANG Yuhan, DAI Min, QIAN Liting. Analysis of lung cancer screening rate and screening results of urban residents in Hefei from 2014 to 2016 [J]. Journal of Practical Oncology, 2021, 35(3): 231-236.
[4]	WANG Junmei, PAN Huiqing, LI Jingyi, JIA Di, ZHAO Weiming, LV Changlian. The expression and clinical significance of MT2-MMP at the stage II of lung adenocarcinoma [J]. Journal of Practical Oncology, 2021, 35(3): 243-247.
[5]	YIN Lei, YANG Xudong, YANG Yue, NIU Xingjian, ZHOU Xiaoping, JI Hongfei, WANG Yiran. The clinical significance and related mechanism of neutrophil to lymphocyte ratio in the prognostic evaluation of patients with non small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 117-124.
[6]	JIAO Zhiyun, DU Fang, HE Ling, YUAN Baofeng. Preliminary study of dynamic contrast-enhanced magnetic resonance imaging in mediastinal lymph node metastasis of lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 142-147.
[7]	LI Ruiyang,FANG Lin,ZHANG Yanqiao. Research progress on immunotherapy of esophageal cancer [J]. Journal of Practical Oncology, 2021, 35(1): 41-45.
[8]	LIU Xuejing,XU Yanying. Research progress of B7-H6 in malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 46-49.
[9]	DONG Cheng,DUAN Yong. Research progress on the mechanism and treatment of Dickkopf family protein in non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(1): 64-68.
[10]	BAO Yu,ZHU Lijian,QIAN Jiang. New progress in the research of anti-angiogenic drugs in the treatment of lung cancer with brain metastases [J]. Journal of Practical Oncology, 2021, 35(1): 91-96.
[11]	ZUO Rui, JIN Lu, LIU Li, LIU Xiaojia, ZHAO Pengyu, XIANG Xiaoyan. Research progress of miR-409-3p and tumor [J]. Journal of Practical Oncology, 2020, 34(6): 554-559.
[12]	YAN Yan, HOU Lifang, LI Renfei, YAN Peng, WANG Yuedong, ZHENG Yuting. Imaging with ^99mTc-HYNIC-MPG molecular typing of non-small cell lung cancer in vivo [J]. Journal of Practical Oncology, 2020, 34(5): 412-417.
[13]	CHENG Yue, ZHANG Mingyan, ZHANG Wenbo, XU Hui. Research progress of lncRNAs as members of ceRNAs networks in lung cancer [J]. Journal of Practical Oncology, 2020, 34(5): 451-455.
[14]	ZHAO Rencheng, LIN Zitang, YU Weijun, LEI Lin, LIU Zheng, XU Ying, GUO Yanfang, PENG Ji. Analysis of the prevalence of five cancer risks among permanent residents aged 40~74 years old in Baoan District,Shenzhen,2017—2019 [J]. Journal of Practical Oncology, 2020, 34(4): 315-320.
[15]	MENG Ruirui, LIU Yuanyuan, GUAN Xinli, ZHOU Peng, XU Guohui. Status and progress of low-dose spiral CT in lung cancer screening [J]. Journal of Practical Oncology, 2020, 34(4): 372-376.

Research progress in anti-tumor effect of propofol and its molecular mechanism in lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments